6:30 AM-7:45 AM Complimentary Continental Breakfast Provided
6:30 AM-6:30 PM Exhibits

7:00 AM-7:45 AM

Breakout Session: Immunology 101: Tools and Assays Used in Clinical Trials


Mary L. (Nora) Disis, MD
University of Washington


Panel Question and Answer

7:55 AM-9:30 AM

Welcome and General Session 4: Immune Biomarkers in the Blood


Lisa H. Butterfield, PhD—Chair
University of Pittsburgh Cancer Institute/Hillman Cancer Center


Mary L. (Nora) Disis, MD
University of Washington



Jeffrey Schlom, PhD
National Cancer Institute at the National Institutes of Health

Immune Cell Subsets and Functional Markers


Jolanda De Vries, PhD
Radboud Institute for Molecular Life Sciences

Imaging Inflammation


Theresa L. Whiteside, PhD
University of Pittsburgh Cancer Institute

PD-L1 Expression Within Exosomes as Marker or Response


Sacha Gnjatic, PhD
Icahn School of Medicine at Mount Sinai

Serologic Markers of Immune Response


Lisa H. Butterfield, PhD
University of Pittsburgh Cancer Institute/Hillman Cancer Center

Biomarkers Wrap-up


Panel Question and Answer

9:30  AM-10:00 AM Break
10:00 AM-11:30 AM

General Session 5: Immune Biomarkers in the Tumor


Luis A. Diaz, MD—Chair
Memorial Sloan Kettering Cancer Center


Weiping Zou, MD, PhD
University of Michigan
PD-L1 Expression and Blueprint Project


Timothy A. Chan, MD, PhD
Memorial Sloan Kettering Cancer Center

Mutational Burden as an Indicator of Response


Jennifer Jones, MD
Center for Cancer Research, National Institutes of Health

Exosomes by Flow Cytometry


Panel Question and Answer

11:45 AM-1:00 PM

Networking Roundtables: Focus on Career Development


Expert faculty willl lead small-group discussions on general networking and career development, particularly for early-career attendees.


For a list of the faculty participants, please visit Networking Opportunities.

11:30 AM-1:00 PM

Poster Session B

With Complimentary Boxed Lunch

1:00 PM-2:15 PM

Oral Abstract Session B

Stephen M. Ansell, MD, PhD - Co-Chair

Mayo Clinic

Howard L. McLeod, PharmD - Co-Chair

Moffitt Cancer Center


Abstract 1: Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab.

First author: Razvan Cristescu


Abstract 2: Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma.

First author: Vancheswaran Gopalakrishnan


Discussion: Shridar Ganesan, MD, PhD

Rutgers Cancer Institute of New Jersey


Abstract 3: Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.

First author: Kavita Dhodapkar


Abstract 4: Association of soluble PD-L1 (sPD-L1) with decreased survival in metastatic melanoma.

First author: Roxana Dronca


Discussion: Douglas McNeel, MD, PhD

University of Wisconsin


Panel Question and Answer

2:15 PM-3:00 PM

Keynote Lecture


Robert Schreiber, PhD
Washington University in St. Louis

Neoantigens and Checkpoint Blockades

3:00 PM-3:30 PM Break
3:30 PM-5:00 PM

General Session 6: Manipulating Innate Immunity in Cancer Therapy


Marka R. Crittenden, MD, PhD—Chair
Earle A. Chiles Research Institute, Providence Cancer Center


Branimir I. Sikic, MD
Stanford University School of Medicine
CD47 Targeted Antibodies and SIRP Alpha-Fc Molecules


Dmitry Gabrilovich, MD, PhD
The Wistar Institute

Myeloid Cells and How They Suppress Immunity


Thomas Gajewski, MD, PhD
The University of Chicago

STING Trials and Creating a Danger Signal in Tumors


Jeffrey S. Miller, MD
University of Minnesota

NK Cells: Ready for Clinical Prime Time?


Panel Question and Answer

5:00 PM-5:30 PM

Evening Highlights: How Will Today’s Presentations Impact Clinical Practice?


Elizabeth A. Mittendorf, MD, PhD
University of Texas MD Anderson Cancer Center


Panel Question and Answer

5:30 PM-6:30 PM

Poster Session B (Continued) and Networking Reception

With Complimentary Wine and Cheese

5:45 PM-6:30 PM

Poster Walks


Ravi Madan, MD
National Cancer Institute


Lisa Butterfield, PhD
University of Pittsburgh Cancer Institute/Hillman Cancer Center